Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Recurrence 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Negative T790M Mutation and Met Amplification 1C-Met Exon 14 Mutation 1Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors 1

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumor × glumetinib × Clear all
NCT03457532 2024-11-01

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

Haihe Biopharma Co., Ltd.

Phase 1 Completed
177 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03466268 2024-10-09

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

Haihe Biopharma Co., Ltd.

Phase 1 Completed
56 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡